TR199800644T2 - Bir apoptoz inhibitörü olarak y-RAR antagonist ligandi ya da alfa-RAR antagonist ligandi. - Google Patents

Bir apoptoz inhibitörü olarak y-RAR antagonist ligandi ya da alfa-RAR antagonist ligandi.

Info

Publication number
TR199800644T2
TR199800644T2 TR1998/00644T TR9800644T TR199800644T2 TR 199800644 T2 TR199800644 T2 TR 199800644T2 TR 1998/00644 T TR1998/00644 T TR 1998/00644T TR 9800644 T TR9800644 T TR 9800644T TR 199800644 T2 TR199800644 T2 TR 199800644T2
Authority
TR
Turkey
Prior art keywords
rar antagonist
antagonist ligand
alpha
ligand
apoptosis inhibitor
Prior art date
Application number
TR1998/00644T
Other languages
English (en)
Inventor
Fesus Laszlo
Szondy Zsuzsa
Reichert Uwe
Original Assignee
Centre International De Recherches Dermatologiques Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre International De Recherches Dermatologiques Galderma filed Critical Centre International De Recherches Dermatologiques Galderma
Publication of TR199800644T2 publication Critical patent/TR199800644T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

En azindan bir hücre popülasyonunda apoptoz oraninin düsürülmesi için bir farmasötik bilesimin hazirlanmasi için bir y-RAR reseptörüne özgü antagonist ligandi ve bir alfa-RAR reseptörüne özgü agonist ligandindan seçilen en azindan bir ligandin kullanilmasi . Bilesim, en azindan bir hücre popülasyonunda asiri bir apoptoz orani ile iliskili bir hastalik ya da düzensizligin iyilestirilmesi için özellikle müsaittir.
TR1998/00644T 1995-10-11 1996-10-08 Bir apoptoz inhibitörü olarak y-RAR antagonist ligandi ya da alfa-RAR antagonist ligandi. TR199800644T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9511946A FR2739777B1 (fr) 1995-10-11 1995-10-11 Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose

Publications (1)

Publication Number Publication Date
TR199800644T2 true TR199800644T2 (tr) 1998-07-21

Family

ID=9483437

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/00644T TR199800644T2 (tr) 1995-10-11 1996-10-08 Bir apoptoz inhibitörü olarak y-RAR antagonist ligandi ya da alfa-RAR antagonist ligandi.

Country Status (21)

Country Link
US (1) US6063797A (tr)
EP (1) EP0854711B1 (tr)
JP (1) JP3135267B2 (tr)
KR (1) KR100300214B1 (tr)
CN (1) CN1104896C (tr)
AT (1) ATE212226T1 (tr)
AU (1) AU695311B2 (tr)
BR (1) BR9611035A (tr)
CA (1) CA2231558C (tr)
DE (1) DE69618802T2 (tr)
DK (1) DK0854711T3 (tr)
ES (1) ES2172680T3 (tr)
FR (1) FR2739777B1 (tr)
HU (1) HUP9900037A3 (tr)
NO (1) NO981652L (tr)
NZ (1) NZ319647A (tr)
PL (1) PL186821B1 (tr)
PT (1) PT854711E (tr)
RU (1) RU2191008C2 (tr)
TR (1) TR199800644T2 (tr)
WO (1) WO1997013506A1 (tr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10158192A (ja) * 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
FR2776511B1 (fr) * 1998-03-31 2001-05-11 Galderma Rech Dermatologique Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique
IL142094A0 (en) * 1998-09-29 2002-03-10 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6713515B2 (en) * 2000-09-13 2004-03-30 Bristol Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) * 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
KR20070086329A (ko) * 2004-12-17 2007-08-27 와이어쓰 에스트로겐 베타 아고니스트의 신규 용도
KR100798853B1 (ko) * 2005-02-15 2008-01-28 (주)한국스티펠 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
EA026251B1 (ru) * 2010-09-01 2017-03-31 Томас Джефферсон Юниверсити Способ восстановления и регенерации мышц
IN2014MN01680A (tr) 2012-02-13 2015-07-03 Gamida Cell Ltd
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9861640B2 (en) 2013-06-10 2018-01-09 Kemphys Ltd. Medicament for treatment of Alzheimer's disease
WO2016144976A1 (en) * 2015-03-09 2016-09-15 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
IL254697B (en) 2015-03-31 2022-08-01 Syros Pharmaceuticals Inc Methods for stratifying patients for treatment with retinoic acid alpha receptor agonists
WO2017174999A1 (en) * 2016-04-07 2017-10-12 High Force Research Limited Synthetic retinoids for use in rar mediated conditions
CA3020173A1 (en) 2016-04-08 2017-10-12 Syros Pharmaceuticals, Inc. Rara agonists for the treatment of aml and mds
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
FR2713640B1 (fr) * 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
FR2722985B1 (fr) * 1994-07-27 1996-09-13 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations

Also Published As

Publication number Publication date
ATE212226T1 (de) 2002-02-15
BR9611035A (pt) 1999-07-06
AU695311B2 (en) 1998-08-13
FR2739777B1 (fr) 1997-11-14
HUP9900037A2 (hu) 1999-04-28
EP0854711A1 (fr) 1998-07-29
JPH11500448A (ja) 1999-01-12
DE69618802D1 (de) 2002-03-14
DK0854711T3 (da) 2002-03-25
PT854711E (pt) 2002-05-31
PL186821B1 (pl) 2004-03-31
CN1203529A (zh) 1998-12-30
EP0854711B1 (fr) 2002-01-23
KR100300214B1 (ko) 2001-11-22
DE69618802T2 (de) 2002-11-14
CA2231558C (fr) 2003-05-27
KR19990064204A (ko) 1999-07-26
PL326162A1 (en) 1998-08-31
NZ319647A (en) 2000-06-23
NO981652D0 (no) 1998-04-08
NO981652L (no) 1998-06-10
JP3135267B2 (ja) 2001-02-13
RU2191008C2 (ru) 2002-10-20
WO1997013506A1 (fr) 1997-04-17
HUP9900037A3 (en) 1999-11-29
CN1104896C (zh) 2003-04-09
US6063797A (en) 2000-05-16
ES2172680T3 (es) 2002-10-01
FR2739777A1 (fr) 1997-04-18
AU7221096A (en) 1997-04-30
CA2231558A1 (fr) 1997-04-17

Similar Documents

Publication Publication Date Title
TR199800644T2 (tr) Bir apoptoz inhibitörü olarak y-RAR antagonist ligandi ya da alfa-RAR antagonist ligandi.
TR200000740T2 (tr) Dişleri beyazlatmak için metod ve kompozisyonlar.
TR200001982T2 (tr) Farmasötik vurulu salınımlı oral dozaj şekli.
ES2161279T3 (es) Nucleosidos y nucleotidos que contienen racimos de boro.
NO975716L (no) Imidazolforbindelser
PT935465E (pt) Compostos novos de imidazole substituido
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
DE59710893D1 (de) Kosmetische oder pharmazeutische zubereitungen mit vermindertem klebrigkeitsgefühl
PT831837E (pt) Utilizacao de esqualamina no fabrico de um medicamento para inibicao de nhe
ATE221881T1 (de) Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat
ES2188759T3 (es) Derivados de la dolastatina, su preparacion y su uso.
PT998460E (pt) Novos derivados de tetrazole
ATE239709T1 (de) Racemisches huperzin a
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
TR199701520T1 (tr) Acinin iyilestirilmesi için analjesik bilesikleri üreten hücre soyu.
DE69625230D1 (de) Thrombininhibitoren
SE9504662D0 (sv) New compounds
IS5390A (is) Bensoxazín og bensóþíazín afleiður og notkun þeirra í lyf
DE69901805T2 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
PT1058544E (pt) Inibicao da actividade do tnf
TR199802577T2 (tr) Ayri bölmelerde iki aktif terkip maddeli transdermik sistemler.
TR199900140T2 (tr) 5HT2C antagonist ve bir D2 antagonist ihtiva eden farmasötik bilesimi.
TR200000074T2 (tr) Yeni terkip
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados